P2RY12 and atrial fibrillation: It was a 2 × 2 factorial designed trial in which patients with AF developed ACS or had PCI and were randomized in a 1:1 fashion to either apixaban 5-mg BID (n = 2,306) or VKA with an INR goal of 2 to 3 (n = 2,308) with either aspirin 81-mg daily (n = 2,307) or matching placebo (n = 2,307) for at least 6 months.26All patients received a P2Y12 inhibitor.